Table 1 Patients demographics in SYSUCC cohort and three validation cohorts (FAHSYSU, CHCAMS 1, and CHCAMS 2)
Characteristics | Total (n = 408) | SYSUCC cohort (n = 131) | FAHSYSU cohort (n = 115) | CHCAMS cohort 1 (n = 101) | CHCAMS cohort 2 (n = 61) |
|---|---|---|---|---|---|
Sex | |||||
Male | 195 (47.79%) | 67 (51.15%) | 57 (49.57%) | 41 (40.59%) | 30 (49.18%) |
Female | 213 (52.21%) | 64 (48.85%) | 58 (50.43%) | 60 (59.41%) | 31 (50.82%) |
Age at diagnosis (years) | |||||
Median | 51 (9.00–87.00) | 51 (9.00–87.00) | 45 (15.00–80.00) | 54 (23.00–75.00) | 55 (21.00–75.00) |
≥55 | 164 (40.20%) | 52 (39.69%) | 31 (26.96%) | 49 (48.51%) | 32 (52.46%) |
<55 | 244 (59.80%) | 79 (60.31%) | 84 (73.04%) | 52 (51.49%) | 29 (47.54%) |
STAT6 expression | |||||
Score 0/1 | 18 (4.41%) | 11 (8.40%) | 2 (1.74%) | 4 (3.96%) | 1 (1.64%) |
Score 2/3 | 390 (95.59%) | 120 (91.60%) | 113 (98.26%) | 97 (96.04%) | 60 (98.36%) |
Tumor sites | |||||
Intra-thoracica | 186 (45.59%) | 62 (47.33%) | 17 (14.78%) | 68 (67.33%) | 39 (63.93%) |
Head and neck | 26 (6.37%) | 7 (5.34%) | 16 (13.91%) | 1 (0.99%) | 2 (3.28%) |
Trunk | 53 (12.99%) | 15 (11.45%) | 24 (20.87%) | 8 (7.92%) | 6 (9.84%) |
Extremity | 15 (3.68%) | 3 (2.29%) | 10 (8.70%) | 1 (0.99%) | 1 (1.64%) |
Intra-abdominal | 70 (17.16%) | 25 (19.08%) | 21 (18.26%) | 12 (11.88%) | 12 (19.67%) |
CNS | 58 (14.22%) | 19 (14.50%) | 27 (23.48%) | 11 (10.89%) | 1 (1.64%) |
Specimen type | |||||
Primary | 356 (87.25%) | 117 (89.31%) | 94 (81.74%) | 90 (89.11%) | 55 (90.16%) |
Recurrence | 42 (10.29%) | 11 (8.40%) | 16 (13.91%) | 10 (9.90%) | 5 (8.20%) |
Metastasis | 10 (2.45%) | 3 (2.29%) | 5 (4.35%) | 1 (0.99%) | 1 (1.64%) |
Margins | |||||
R0a | 391 (95.83%) | 127 (96.95%) | 106 (92.17%) | 98 (97.03%) | 60 (98.36%) |
R1b | 7 (1.72%) | 2 (1.53%) | 1 (0.87%) | 3 (2.97%) | 1 (1.64%) |
R2c | 10 (2.45%) | 2 (1.53%) | 8 (6.96%) | 0 (0.00%) | 0 (0.00%) |
Radiotherapy | |||||
No | 377 (92.40%) | 116 (88.55%) | 106 (92.17%) | 96 (95.05%) | 59 (96.72%) |
Yes | 31 (7.60%) | 15 (11.45%) | 9 (7.83%) | 5 (4.95%) | 2 (3.28%) |
Chemotherapy | |||||
No | 389 (95.34%) | 124 (94.66%) | 109 (94.78%) | 97 (96.04%) | 59 (96.72%) |
Yes | 19 (4.66%) | 7 (5.34%) | 6 (5.22%) | 4 (3.96%) | 2 (3.28%) |
Status | |||||
Recurrence | 47 (11.52%) | 16 (12.21%) | 16 (13.91%) | 8 (7.92%) | 7 (11.48%) |
Metastasis | 29 (7.11%) | 8 (6.11%) | 9 (7.83%) | 8 (7.92%) | 4 (6.56%) |
Died | 11 (2.70%) | 5 (3.82%) | 4 (3.48%) | 0 (0.00%) | 2 (3.28%) |
Progression-free | 325 (79.66%) | 103 (78.63%) | 88 (76.52%) | 85 (84.16%) | 49 (80.33%) |
Metastatic sites | |||||
Pleura/lung | 7 (1.72%) | 1 (0.76%) | 1 (0.87%) | 3 (2.97%) | 2 (3.28%) |
Liver | 5 (1.23%) | 2 (1.53%) | 1 (0.87%) | 1 (0.99%) | 1 (1.64%) |
Bone | 6 (1.47%) | 1 (0.76%) | 3 (2.61%) | 2 (1.98%) | 0 (0.00%) |
Peritoneum/intraperitoneal | 4 (0.98%) | 0 (0.00%) | 4 (3.48%) | 0 (0.00%) | 0 (0.00%) |
Lymphonodus | 2 (0.49%) | 2 (1.53%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
Brain | 5 (1.23%) | 2 (1.53%) | 0 (0.00%) | 2 (1.98%) | 1 (1.64%) |
Follow-up time (months) | 36.90 (0.00–171.30) | 41.10 (0.80–171.30) | 29.10 (0.00–121.20) | 32.20 (0.00–73.90) | 62.30 (0.30–121.10) |
